Clinical trials: Tumor Angiogenesis
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Metastatic Colorectal Cancer, Liver Metastases
FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
This is an open label single arm prospective multicenter Phase II study in around 20 patients. The primary objective of this study is to evaluate whether the addition of sunitinib to FOLFIRI results in a significant reduction of…
- Trial name
- NCT00806663
- Testing
- sunitinib added to FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Placenta Previa
Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach.
- Trial name
- VEGF PP (NCT06620068)
- Volunteers
- 207,473 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Adenocarcinoma of the Lung
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung…
- Trial name
- NCT04459078
- Testing
- Camrelizumab, Albumin Paclitacxel, Apatinib
- Where
- 3 sites in China
- Volunteers
- 63 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
Bevacizumab, an anti-angiogenic agent, plus fluorouracil based chemotherapy is considered a new standard for the treatment of metastatic colorectal cancer.
- Trial name
- NCT00489697
- Testing
- real-time contrast-enhanced ultrasound imaging (CEUS)
- Where
- 12 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Tours
Age-related Muscle Decline
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding…
- Trial name
- CALM-AF-AI (NCT07443826)
- Testing
- AAV9-Follistatin gene therapy, VEGF Plasmid
- Where
- Honduras
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Unlimited Biotechnology LLC
Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab, nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.
- Conditions
- Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms
- Trial name
- NCT04725448
- Testing
- Toripalimab, Bevacizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Non Small Cell Lung Cancer, Lung Neoplasms
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
This is a prospective, single-arm phase II clinical study. It intends to evaluate the efficacy and safety of stereotactic radiation therapy (SRT) combined with envafolimab and endostar as first-line treatment in stage IV…
- Trial name
- Endouble 2 (NCT07818304)
- Testing
- Stereotactic Radiation Therapy, Envafolimab, Endostar
- Where
- China
- Volunteers
- 61 people
- Sponsor
- The First People's Hospital of Lianyungang
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Pancreatic Cancer
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
- Trial name
- NCT01707758
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas
Neurofibromatosis Type I, Plexiform Neurofibroma
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Background: Patients with neurofibromatosis type 1 are at increased risk of developing tumors called plexiform neurofibromas (PN) that arise from nerves.
- Trial name
- NCT00727233
- Testing
- Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Sclerosis
MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis
This study will use magnetic resonance imaging (MRI) to examine and compare changes in blood flow and blood volume in the brains of normal volunteers and patients with multiple sclerosis (MS).
- Trial name
- NCT00064909
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Flap Monitoring, Inflammation
Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient
This double-blinded randomized controlled trial aims to investigate the effect of intraoperative dexmedetomidine administration on early flap viability and microvascular integrity in cancer patients undergoing elective…
- Conditions
- Flap Monitoring, Inflammation, Thrombosis, Oxidative Stress
- Trial name
- DEXFLAP (NCT06993740)
- Testing
- NaCl 0,9%, Dexmedetomidine
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Dharmais National Cancer Center Hospital
Adult Solid Neoplasm
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
This phase I trial studies the side effects and best dose of sunitinib malate when given together with hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy.
- Trial name
- NCT00813423
- Testing
- Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
Colorectal cancer patients with metastases (mCRC) at response under expensive chemotherapy which may be toxic +/- exhausting are candidates for an effective and more convenient maintenance treatment. Objectives: 1.
- Trial name
- NCT01668680
- Testing
- CAPECITABINE, CELECOXIB and METHOTREXATE
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- HaEmek Medical Center, Israel
Sarcoma
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00023725
- Testing
- semaxanib, conventional surgery, radiation therapy
- Where
- 226 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced / Metastatic Solid Tumors
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with…
- Trial name
- ASCEND (NCT07335497)
- Testing
- CR-001, Paclitaxel, trifluridine and tipiracil
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 540 people
- Sponsor
- Crescent Biopharma, Inc.
Lung Cancer, Non-Small Cell
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) of pazopanib in combination with erlotinib (Arm A) or pazopanib in…
- Trial name
- NCT00619424
- Testing
- pazopanib, erlotinib, pemetrexed
- Where
- 4 sites in United States, Italy
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Glioblastoma
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Temozolomide (TMZ) is an oral chemotherapy drug. It is an alkylating agent used as a first-line treatment for glioblastoma. This methylation damages the DNA and triggers the death of tumor cells.
- Trial name
- NCT03567135
- Testing
- Apatinib, Temozolomide（TMZ）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuzhou General Hospital